ALEC Insider Trading

Insider Ownership Percentage: 9.10%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $718,275.08

Alector Insider Trading History Chart

This chart shows the insider buying and selling history at Alector by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$2M$0$2MTotal Insider BuyingTotal Insider Selling

Alector Share Price & Price History

Current Price: $0.95
Price Change: Price Increase of +0.0457 (5.05%)
As of 04/11/2025 05:00 PM ET

This chart shows the closing price history over time for ALEC up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
MayJunJulAugSepOctNovDecJanFebMarApr$0.95Closing price on 04/11/25:

SEC Filings (Institutional Ownership Changes) for Alector (NASDAQ:ALEC)

85.83% of Alector stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at ALEC by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$13Mbought$2.51MsoldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$10M-$5M$0$5M$10MTotal InflowsTotal Outflows
Alector logo
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.
Read More on Alector

Today's Range

Now: $0.95
Low: $0.90
High: $0.97

50 Day Range

MA: $1.43
Low: $0.90
High: $1.87

52 Week Range

Now: $0.95
Low: $0.87
High: $6.78

Volume

565,681 shs

Average Volume

773,286 shs

Market Capitalization

$94.13 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.73

Who are the company insiders with the largest holdings of Alector?

Alector's top insider investors include:
  1. Polaris Venture Management Co (Major Shareholder)
  2. Arnon Rosenthal (CEO)
  3. Sara Kenkare-Mitra (Insider)
  4. Marc Grasso (CFO)
  5. Gary Romano (Insider)
  6. Paula Hammond (Director)
Learn More about top insider investors at Alector.